News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline Kidney Cancer Drug Shrinks Thyroid Tumors
September 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHICAGO, Sept 17 (Reuters) - In a small study, GlaxoSmithKline's (GSK.L) cancer drug Votrient helped shrink tumors in nearly half of patients with an advanced form of thyroid cancer, U.S. and international researchers said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Postmarket research
GlaxoSmithKline
MORE ON THIS TOPIC
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
·
3 min read
·
Annalee Armstrong
Vaccines
Does Vaxart Hold the Key to the Elusive Norovirus Vaccine?
February 17, 2026
·
3 min read
·
Dan Samorodnitsky
Immunology and inflammation
Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
February 17, 2026
·
2 min read
·
Tristan Manalac